Catalyst (CPRX) Reports Q3 Loss As Expected & Pipeline Update
Zacks Investment Research | Nov 09, 2018 03:17AM ET
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported a loss of 8 cents per share in the third quarter of 2018, in-line with the Zacks Consensus Estimate of a loss of 8 cents but wider than the year-ago loss of 5 cents.
Being a development-stage company, Catalyst does not have any approved product in its portfolio yet. Hence, the company did not generate any revenues in the quarter.
So far this year, Catalyst’s shares have lost 21.2% compared with the industry ’s 2.7% decline.
Quarter in Detail
Research and development (R&D) expenses were $4.5 million, up 67.8% from the year-ago quarter. Costs during the first nine months of 2018 increased due to rise in consulting expenses as Catalyst prepared to submit its new drug application (NDA) for Firdapse during the first quarter of 2018, milestone expenses in connection with the acceptance of Catalyst’s NDA submission in May 2018. They also included expenses from Catalyst’s medical affairs program, and compensation and related personnel costs, as Catalyst expands its headcount to support currently ongoing trials and programs.
General and administrative expenses totaled $3.6 million, up 127.5% from the year-ago quarter. The increase in expenses is attributable to higher pre-commercialization expenses, headcount costs and corporate expenses as Catalyst builds its infrastructure and commercial programs to prepare for a potential launch of Firdapse in 2019.
Pipeline Update
Currently, Catalyst has two candidates under development — Firdapse and CPP-115.
The FDA accepted the NDA for Firdapse, which the company had resubmitted for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The FDA also granted a priority review status to the NDA and an action date of Nov 28, 2018 is set for the same. The company expects to launch Firdapse in early 2019 assuming approval.
Catalyst expects top-line results from Firdapse’s phase III study for MuSK antibody positive myasthenia gravis in the second half of 2019.
The company also expects top-line results from the phase III congenital myasthenic syndromes (CMS) (CMS-001) study in the second half of 2019.
Get The News You Want
Zacks Rank & Stocks to Consider
Catalyst has a Zacks Rank #3 (Hold).
Some top-ranked stocks worth considering are Bristol-Myers Squibb Company (NYSE:BMY) , Eli Lilly and Company (NYSE:LLY) and Merck & Co. Inc. (NYSE:MRK) . While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), Lilly and Merck carry a Zacks Rank #2 (Buy). You can see .
Bristol-Myers’ earnings per share estimates have increased from $3.59 to $3.84 for 2018 and from $3.83 to $4.07 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 11.99%.
Lilly’s earnings per share estimates have increased from $5.42 to $5.51 for 2018 and from $5.69 to $5.79 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10.03%. Shares of the company have increased 30.4% year to date.
Merck’s earnings per share estimates have increased from $4.26 to $4.34 for 2018 and from $4.58 to $4.71 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 3.96%. Shares of the company have increased 34.1% year to date.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.